Kenneth Bingener, DO
Family Medicine · Boyertown, PANPI 1841266657
Payments from drug & device makers
Across 247 payments — averaging $18.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$846
- Bayer$534
- Lilly USA, LLC$524
- AstraZeneca$428
- Abbott$346
- AbbVie$332
- plus $2K from 26 others
What the payments were for
- Speaking & faculty fees$45010%
- Food & beverage$4,11889%
- Education$421%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 46 | $846 |
| Bayer | 7 | $534 |
| Lilly USA, LLC | 35 | $524 |
| AstraZeneca | 26 | $428 |
| Abbott | 19 | $346 |
| AbbVie(2 entities) | 21 | $332 |
| Pfizer | 24 | $292 |
| Boehringer Ingelheim | 10 | $202 |
| GSK | 9 | $183 |
| Amgen | 6 | $107 |
| Sanofi-aventis U.S. LLC | 6 | $87 |
| Novartis | 4 | $84 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $70 |
| Mannkind Corporation | 3 | $61 |
| Bausch & Lomb Americas Inc. | 1 | $54 |
| Merck | 3 | $53 |
| Amarin Pharma, Inc. | 3 | $43 |
| Kowa Pharmaceuticals America, Inc. | 3 | $40 |
| Johnson & Johnson | 3 | $38 |
| Exact Sciences | 2 | $34 |
| Astellas Pharma US Inc | 1 | $31 |
| Insulet Corporation | 1 | $29 |
| Sumitomo Pharma America, Inc. | 1 | $27 |
| Inspire Medical Systems, Inc. | 1 | $22 |
| Azurity Pharmaceuticals, Inc. | 1 | $21 |
| Alnylam Pharmaceuticals Inc. | 1 | $20 |
| Dexcom, Inc. | 1 | $19 |
| Acella Pharmaceuticals, LLC | 1 | $19 |
| Sanofi Pasteur Inc. | 1 | $17 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Tolmar, Inc. | 1 | $16 |
| Eisai Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$450
How this compares
$4,609 in reported general payments places this provider in the 85th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 186 | $148,247 |
| KerendiaFinerenone | 91 | $73,451 |
| JanuviaSitagliptin Phosphate | 42 | $56,929 |
| OzempicSemaglutide | 39 | $51,888 |
| JardianceEmpagliflozin | 54 | $50,215 |
| FarxigaDapagliflozin Propanediol | 51 | $45,334 |
| Tresiba Flextouch U-200Insulin Degludec | 35 | $36,508 |
| MounjaroTirzepatide | 29 | $30,842 |
| Tresiba Flextouch U-100Insulin Degludec | 52 | $30,733 |
| XareltoRivaroxaban | 24 | $22,822 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 16 | $13,451 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 23 | $11,826 |
| TradjentaLinagliptin | 14 | $10,405 |
| Atorvastatin Calcium | 955 | $9,689 |
| EntrestoSacubitril/Valsartan | 16 | $7,472 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $292 | $148,247186 claims |
| BayerKerendia | $534 | $73,45191 claims |
| MerckJanuvia, Janumet Xr | $53 | $63,87555 claims |
| Boehringer IngelheimJardiance, Tradjenta | $202 | $60,62068 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $428 | $52,16862 claims |
| Novo NordiskOzempic | $846 | $51,88839 claims |
| Lilly USA, LLCMounjaro | $524 | $30,84229 claims |
| Johnson & JohnsonXarelto | $38 | $22,82224 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $87 | $13,45116 claims |
| NovartisEntresto | $84 | $7,47216 claims |
| AbbVieSynthroid | $332 | $3,12739 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Boyertown
- Kem YenalPhila$12.6M
- Marcy FleckerSmithfield$6.9M
- Tiffany PlutoScottdale$4.8M
- Bryce PalchickPittsburgh$4.7M
- Harris CohenHorsham$3.7M
- Shari RozenPittsburgh$2.9M
- Richard CookUniontown$2.1M
- Bruce GebhardtErie$2.1M
- Peter CognettiScranton$1.9M
- Bradley FoxErie$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.